(NASDAQ: BTAI) Bioxcel Therapeutics's forecast annual revenue growth rate of 379.07% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.34%.
Bioxcel Therapeutics's revenue in 2026 is $642,000.On average, 7 Wall Street analysts forecast BTAI's revenue for 2026 to be $42,750,771, with the lowest BTAI revenue forecast at $15,070,798, and the highest BTAI revenue forecast at $93,813,440. On average, 6 Wall Street analysts forecast BTAI's revenue for 2027 to be $420,495,395, with the lowest BTAI revenue forecast at $108,785,687, and the highest BTAI revenue forecast at $872,749,280.
In 2028, BTAI is forecast to generate $2,254,852,746 in revenue, with the lowest revenue forecast at $1,679,544,868 and the highest revenue forecast at $2,842,831,530.